Good morning, ladies and gentlemen. I am David Hochman, Chief Executive Officer and Chairperson of the Board of Directors of Orchestra BioMed Holdings, Inc. It's my pleasure to welcome you to our 2026 annual meeting of stockholders. We're delighted that you were able to join us today for this virtual meeting. As chairperson of this meeting, I hereby call the meeting to order and appoint Andrew Taylor, the company's Chief Financial Officer and Secretary, to serve as the secretary of this meeting. I would also like to introduce Steve Matzek of Ernst & Young LLP, our independent registered public accounting firm. During the Q&A period at the end of today's session, Mr. Matzek will be available to answer any appropriate questions you may have concerning the independent audit. The company has appointed Ken Franke of Broadridge Financial Solutions to act as Inspector of Election for the meeting. Mr. Franke has previously taken his oath as Inspector of Election, and will file the executed oath with the records of this meeting. Many stockholders have already submitted their proxies. All proxies will be voted as marked by the stockholders signing them. If you have voted by proxy, you do not need to take any further action unless you want to change your vote by voting at this meeting. If you wish to vote during this meeting, please log in as a stockholder by entering the 16-digit control number you receive with your proxy materials and clicking on the Vote Here button on your screen. The secretary will now review the agenda, rules of conduct, and procedures for today's meeting and present the affidavit of mailing of the notice of the meeting. Thank you, David. Upon logging into the meeting, all participants were presented with an agenda and the rules of conduct and procedures for the annual meeting. To conduct an orderly meeting, we ask that participants abide by these rules. As stated in the rules of conduct, only validated stockholders may ask questions in the designated field on the web portal. Should you desire to ask a question during the meeting, please submit your question in the designated field on the web portal. After the formal meeting has been adjourned, we will attempt to answer as many questions as time allows, but only questions that are relevant to the meeting will be addressed. Thank you for your cooperation with these rules. There are five items of business on today's agenda. The election of 3 Class III directors, the vote on the ratification of the appointment of the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026, the vote on the approval of the Orchestra BioMed Holdings, Inc. 2026 employee stock purchase plan, the advisory vote on the compensation of the company's named executive officers, and the advisory vote on the frequency of future votes on the compensation of the company's named executive officers. Each of these items is described in the company's proxy statement filed with the SEC on April 29th, 2026. The board of directors set April 28th, 2026, as the date of record for this stockholders meeting. We have at this meeting a record of stockholders as of that date. A duplicate record has been on file at the principal place of the business of the company and has been available for inspection by any stockholder during normal business hours since June 12, 2026. Mr. Chairperson, I present the affidavit of mailing signed by Joanne Vogel of Broadridge Financial Solutions, which states that the records relating to the meeting were mailed and deposited with the post office commencing on April 30, 2026. Thank you, Andrew. I direct that the affidavit of mailing be made part of the minutes of the meeting. Our first order of business at this meeting is to determine whether the shares represented at the meeting are sufficient to constitute a quorum for the purpose of transacting business. Andrew, do you have a report? Yes. I have been advised by the Inspector of Election that approximately 81.91% of the company's issued and outstanding shares entitled to vote is represented at today's meeting, which is sufficient to constitute a quorum for the purpose of transacting business at this meeting. Thank you, Andrew. The report of the Secretary on the existence of a quorum is accepted. Since more than one-third of the company's shares are represented here today, I declare that a quorum is present and the meeting is duly constituted. It is 12:05 P.M. Eastern Time. The polls are now open for voting. If you wish to vote now, whether or not you already submitted a proxy, you may vote using the web portal. We may now proceed to transact the business for which this meeting has been called. The next order of business is a description of matters properly brought before this meeting. The first proposal is for the election of Class III directors. Three directors should be elected at today's meeting, each to serve a three-year term until the 2029 annual meeting of stockholders, or until his successor is duly elected and is qualified. As indicated in the company's proxy statement, the board of directors has nominated and recommends a vote for each of David Hochman, Darren Sherman, and Eric Fain, each a current director of the company. The company's bylaws require that a stockholder provide advanced notice to the company of a stockholder's intent to nominate persons as directors. No such notice was received. Accordingly, I declare the nominations for directors closed. There are no questions regarding this proposal. We will now move to proposal 2. The second proposal being submitted to stockholders for action is the ratification of the appointment of Ernst & Young as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Are there any questions? Yeah, sorry. No questions regarding this proposal. We will now move to proposal three. The third proposal being submitted to stockholders for action is a vote on the approval of the Orchestra BioMed Holdings, Inc. 2026 employee stock purchase plan. Are there any questions? There are no questions regarding this proposal. We will now move to proposal four. The fourth proposal being submitted to stockholders for action is the advisory vote on the compensation of our named executive officers. Once again, are there any questions on this proposal? There are no questions regarding this proposal. We now move to proposal five. The fifth proposal being submitted to stockholders for action is the advisory vote on the frequency of future votes on the compensation of the company's named executive officers. Are there any questions on this proposal? There are no questions regarding this proposal. No further business is scheduled to come before the stockholders, we will move on to voting. I now direct that a vote of the stockholders be taken on the foregoing matters. Each holder of common stock is entitled to one vote for each share of common stock held of record at the close of business on April 28th, 2026. Any stockholder who has previously given his or her or its proxy need not vote unless he, she, or it desires to revoke the proxy and vote by electronic ballot at this meeting. No ballots or proxies or revocations or changes of proxies will be accepted after the polls are closed. I declare the polls for each matter voted upon at this meeting closed at 12:08 P.M. Eastern Time today and direct the Inspector of Election to tabulate the ballots. Will the Secretary please report the preliminary results of the voting? Yes. Although not all the numbers on the share votes are in, I can provide the following preliminary results from the Inspector of Election. Starting with the first proposal, Mr. David Hochman, Mr. Darren Sherman, and Dr. Eric Fain have been elected as Class III directors. The second proposal, the ratification of the appointment of Ernst & Young to act as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026, has been approved. The third proposal, the approval of the Orchestra BioMed Holdings, Inc. 2026 employee stock purchase plan, has been approved. The fourth proposal, the advisory vote on the compensation of the company's named executive officers, has been approved. For the fifth proposal, the advisory vote on the frequency of future votes on the compensation of the company's named executive officers, stockholders have selected a frequency of every one year. The Inspector of Election has indicated that he will furnish me with a written report of the final vote count with respect to the matters voted on today. A final tally of the votes will be published in a current report on Form 8-K to be filed with the SEC on or before June 29th, 2026. Thank you, Andrew. Please include the Inspector of Election's written report of the final vote count in the minutes for today's meeting. There being no further business to come before the meeting, the 2026 annual meeting of stockholders of Orchestra BioMed Holdings, Inc. is now adjourned. We would like to answer any stockholder questions that we receive today in the web portal. Please note we will attempt to answer as many questions as time allows, but only questions that are relevant to the meeting will be addressed. For questions about our business, product candidates, and clinical studies, please visit the investor relations section of our website to access the periodic reports that we file with the SEC, which can be accessed by clicking on the financial and filings subheading. Will the Secretary please advise if we have any questions? We have no questions for the purposes that relate to this meeting. This concludes our Q&A session. Thank you all for attending today's meeting and for your continuing support of Orchestra BioMed. Have a great day. The meeting has now concluded. Thank you for joining, and have a pleasant day.